Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma
HARRISON, N.Y., May 3, 2022. Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that the U.S. Food and Drug Administration...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Melanoma | Pharmaceuticals | Skin Cancer